Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity — Ioannis V. Kostopoulos (2024) | RDL Network
Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity
Kristine A. Frerichs, Christie P.M. Verkleij, Meletios A Dimopoulos, Jhon A. Marin Soto, Sonja Zweegman, Mary H. Young, Kathryn J. Newhall, Tuna Mutis, Niels W.C.J. van de Donk
Discussion(0)
No comments yet. Be the first to comment.